Schmidt, Christian D.

[["dc.bibliographiccitation.firstpage","210"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Prion"],["dc.bibliographiccitation.lastpage","214"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Schmidt, Christian D."],["dc.contributor.author","Becker, Harry"],["dc.contributor.author","Peter, Christoph"],["dc.contributor.author","Lange, Katharina"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T09:42:43Z"],["dc.date.available","2018-11-07T09:42:43Z"],["dc.date.issued","2014"],["dc.description.abstract","Background/Objective: Recently, PrPc has been linked to AD pathogenesis. Second, a relation of PrPc plasma levels with cognitive status and decline of healthy elderly subjects has been reported. Therefore, we hypothesized baseline plasma levels of PrPc to be associated with AD progression in cognitive and functional domains. Methods: AD patients (n = 84) were included into an observational study at time of diagnosis. Baseline plasma PrPc levels were determined. Decline was assessed annually (mean follow-up time 3 years) with the aid of different standardized tests (MMSE, iADL, bADL, GDS, UPDRSIII). Multiple regression analyses were used to uncover potential associations between decline and PrPc levels. Results: No association of PrPc and decline could be established. Presence of diabetes mellitus was linked to slower deterioration. Intake of neuroleptic drugs or memantine was associated with faster progression. Conclusion: Plasma PrPc at baseline could not be shown to be related to AD progression in this study. An interesting association of diabetes mellitus and decline warrants further investigation."],["dc.identifier.doi","10.4161/pri.27964"],["dc.identifier.isi","000343228900010"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34021"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Landes Bioscience"],["dc.relation.issn","1933-690X"],["dc.relation.issn","1933-6896"],["dc.title","Plasma prion protein concentration and progression of Alzheimer disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","189"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Alzheimer s Disease"],["dc.bibliographiccitation.lastpage","196"],["dc.bibliographiccitation.volume","48"],["dc.contributor.author","Schmidt, Christian D."],["dc.contributor.author","Gerlach, Nicole"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Thom, Tobias"],["dc.contributor.author","Kramer, Katharina"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T10:02:58Z"],["dc.date.available","2018-11-07T10:02:58Z"],["dc.date.issued","2015"],["dc.description.abstract","Background/Objective: Apolipoprotein E (ApoE) has an active part in the pathogenesis of Alzheimer's disease (AD). Cerebrospinal fluid (CSF) and plasma level alterations have been reported in AD patients. In search of a biomarker potentially predictive of cognitive, functional, or motor decline, we analyzed the CSF to serum ratios of ApoE levels (CSF/serum ApoE) in AD patients in this regard. Methods: Subjects with newly diagnosed AD were followed within a longitudinal observational study (rpAD study). Annual neuropsychological testing and physical examination were performed. Multiple regression analyses were used to determine possible associations of the ApoE CSF/serum concentration ratios and velocity of decline on a variety of cognitive, functional and motor scales (MMSE, iADL, bADL, GDS, UPDRSIII) adjusted for relevant co-variables. Results: CSF/serum ratios of ApoE levels were associated with progression on the UPDRSIII (change of UPDRSIII slope [pt/yr] per unit of ApoE CSF/serum = -0.06, p < 0.01) and instrumental ADL scale (change of iADL slope [pt/yr] per unit of ApoE CSF/serum = 0.01, p = 0.01) (\"the lower the ratio, the faster the deterioration\" and vice versa). Secondarily, higher age at onset was associated with faster UPDRSIII progression, antidepressant use with faster iADL decline, and better baseline function with more rapid decline on either MMSE, iADL, or GDS scale. Conclusion: Here, CSF/serum ApoE at time of AD diagnosis was shown to be inversely associated with medium-term functional and motor progression. Whether this ratio qualifies for the use as a predictive biomarker must be validated in larger cohort studies over the long term."],["dc.description.sponsorship","Bundesministerium fur Bildung und Forschung (BMBF) [01GI1010C, KNDD-2]"],["dc.identifier.doi","10.3233/JAD-150286"],["dc.identifier.isi","000360931700017"],["dc.identifier.pmid","26401939"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38342"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ios Press"],["dc.relation.issn","1875-8908"],["dc.relation.issn","1387-2877"],["dc.title","Baseline CSF/Serum-Ratio of Apolipoprotein E and Rate of Differential Decline in Alzheimer's Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","A4"],["dc.bibliographiccitation.journal","Astronomy and Astrophysics"],["dc.bibliographiccitation.volume","596"],["dc.contributor.author","Franz, M."],["dc.contributor.author","Collados, M."],["dc.contributor.author","Bethge, C."],["dc.contributor.author","Schlichenmaier, R."],["dc.contributor.author","Borrero, J. M."],["dc.contributor.author","Schmidt, W."],["dc.contributor.author","Lagg, A."],["dc.contributor.author","Solanki, S. K."],["dc.contributor.author","Berkefeld, T."],["dc.contributor.author","Kiess, C."],["dc.contributor.author","Rezaei, R."],["dc.contributor.author","Schmidt, Christian D."],["dc.contributor.author","Sigwarth, M."],["dc.contributor.author","Soltau, D."],["dc.contributor.author","Volkmer, R."],["dc.contributor.author","Luhe, O. von der"],["dc.contributor.author","Waldmann, T."],["dc.contributor.author","Orozco, D."],["dc.contributor.author","Pastor Yabar, A."],["dc.contributor.author","Denker, C."],["dc.contributor.author","Balthasar, H."],["dc.contributor.author","Staude, J."],["dc.contributor.author","Hofmann, A."],["dc.contributor.author","Strassmeier, K."],["dc.contributor.author","Feller, A."],["dc.contributor.author","Nicklas, H."],["dc.contributor.author","Kneer, F."],["dc.contributor.author","Sobotka, M."],["dc.date.accessioned","2020-07-01T07:16:29Z"],["dc.date.available","2020-07-01T07:16:29Z"],["dc.date.issued","2016"],["dc.description.abstract","Context. A significant part of the penumbral magnetic field returns below the surface in the very deep photosphere. For lines in the visible, a large portion of this return field can only be detected indirectly by studying its imprints on strongly asymmetric and three-lobed Stokes V profiles. Infrared lines probe a narrow layer in the very deep photosphere, providing the possibility of directly measuring the orientation of magnetic fields close to the solar surface. Aims. We study the topology of the penumbral magnetic field in the lower photosphere, focusing on regions where it returns below the surface. Methods. We analyzed 71 spectropolarimetric datasets from Hinode and from the GREGOR infrared spectrograph. We inferred the quality and polarimetric accuracy of the infrared data after applying several reduction steps. Techniques of spectral inversion and forward synthesis were used to test the detection algorithm. We compared the morphology and the fractional penumbral area covered by reversed-polarity and three-lobed Stokes V profiles for sunspots at disk center. We determined the amount of reversed-polarity and three-lobed Stokes V profiles in visible and infrared data of sunspots at various heliocentric angles. From the results, we computed center-to-limb variation curves, which were interpreted in the context of existing penumbral models. Results. Observations in visible and near-infrared spectral lines yield a significant difference in the penumbral area covered by magnetic fields of opposite polarity. In the infrared, the number of reversed-polarity Stokes V profiles is smaller by a factor of two than in the visible. For three-lobed Stokes V profiles the numbers differ by up to an order of magnitude."],["dc.identifier.arxiv","1608.00513v2"],["dc.identifier.doi","10.1051/0004-6361/201628407"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66810"],["dc.language.iso","en"],["dc.relation.eissn","1432-0746"],["dc.relation.issn","0004-6361"],["dc.title","Magnetic fields of opposite polarity in sunspot penumbrae"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","229"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Prion"],["dc.bibliographiccitation.lastpage","234"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Schmidt, Christian D."],["dc.contributor.author","Artjomova, Svetlana"],["dc.contributor.author","Hoeschel, Martin"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T09:24:49Z"],["dc.date.available","2018-11-07T09:24:49Z"],["dc.date.issued","2013"],["dc.description.abstract","Background/Objective: PrPc has been suggested to play a role in AD pathophysiology. CSF concentrations of PrPc have been shown to be reduced in AD compared with healthy controls. Furthermore, serum levels of PrPc have recently been reported to be associated with the cognitive status of healthy elderly subjects. Therefore, we hypothesized that CSF levels of PrPc could be associated with cognitive function of AD patients at the time of diagnosis. Results: No association of CSF PrPc and cognitive status could be established, while other factors (i.e., use of antipsychotic drugs, use of anti-dementia drugs, female sex, pre-progression time) were related to worse cognitive function in some domains. Methods: AD patients (n = 114) included into an observational study underwent CERAD testing and lumbar puncture at time of diagnosis / study inclusion. CSF PrPc was determined. Generalized linear models were fitted to assess the associations of PrPc plus a variety of possible confounding factors and CERAD subscale measures. Conclusion: CSF PrPc appears not to be a useful biochemical surrogate of cognitive status in AD at the time of diagnosis. Follow-up analyses will examine possible associations with the speed of cognitive decline."],["dc.identifier.doi","10.4161/pri.23904"],["dc.identifier.isi","000326510900007"],["dc.identifier.pmid","23406922"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29917"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Landes Bioscience"],["dc.relation.issn","1933-690X"],["dc.relation.issn","1933-6896"],["dc.title","CSF prion protein concentration and cognition in patients with Alzheimer disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Prion"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Stoeck, Katharina"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Schmidt, Christian D."],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T09:26:11Z"],["dc.date.available","2018-11-07T09:26:11Z"],["dc.date.issued","2013"],["dc.format.extent","58"],["dc.identifier.isi","000323217500134"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30244"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Landes Bioscience"],["dc.publisher.place","Austin"],["dc.relation.issn","1933-6896"],["dc.title","Immune responses in rapid dementia: A comparative study on neuroinflammatory markers in CJD, AD, rpAD and MS patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1229"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Alzheimer s Disease"],["dc.bibliographiccitation.lastpage","1236"],["dc.bibliographiccitation.volume","43"],["dc.contributor.author","Schmidt, Christian D."],["dc.contributor.author","Gerlach, Nicole"],["dc.contributor.author","Peter, Christoph"],["dc.contributor.author","Gherib, Kerim"],["dc.contributor.author","Lange, Katharina"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T10:04:02Z"],["dc.date.available","2018-11-07T10:04:02Z"],["dc.date.issued","2015"],["dc.description.abstract","Background/Objective: Apolipoprotein E plays a role in the pathogenesis of Alzheimer's disease (AD). Cerebrospinal fluid (CSF) and plasma level alterations have been reported in AD patients. In search of a potential biomarker, which would be predictive of cognitive, functional, or motor decline, we analyzed CSF apolipoprotein E (ApoE) levels of AD patients in this regard. Methods: Subjects with newly diagnosed AD enrolled into an observational study were followed up longitudinally. Neuropsychological testing and physical examination were performed annually. In a sub-cohort of patients, where baseline CSF ApoE concentration values were available, multiple regression analyses were used to determine possible associations of CSF ApoE concentration and speed of decline on different cognitive, functional, and motor scales (MMSE, iADL, bADL, GDS, UPDRSIII) adjusting for possible confounders. Results: No association of CSF ApoE levels and speed of decline on the various scales could be established (p = 0.09 to 0.88). Nevertheless, the use of neuroleptic drugs could be linked to higher velocity of global and extrapyramidal deterioration (p = 0.04 and 0.05 for GDS and UPDRSIII, respectively), but not to other outcomes (MMSE, bADL, and iADL). \\Conclusion: Herein, CSF ApoE at time of AD diagnosis could not be shown to be a viable biomarker for future cognitive, functional, or motor decline. Expectedly, the use of neuroleptic drugs was associated with detrimental effects."],["dc.identifier.doi","10.3233/JAD-141581"],["dc.identifier.isi","000346857400012"],["dc.identifier.pmid","25125466"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38608"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ios Press"],["dc.relation.issn","1875-8908"],["dc.relation.issn","1387-2877"],["dc.title","Cerebrospinal Fluid Apolipoprotein E Concentration and Progression of Alzheimer's Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","10518"],["dc.bibliographiccitation.issue","35"],["dc.bibliographiccitation.journal","Angewandte Chemie International Edition"],["dc.bibliographiccitation.lastpage","10521"],["dc.bibliographiccitation.volume","55"],["dc.contributor.author","Jaremko, Mariusz"],["dc.contributor.author","Jaremko, Lukasz"],["dc.contributor.author","Villinger, Saskia"],["dc.contributor.author","Schmidt, Christian D."],["dc.contributor.author","Griesinger, Christian"],["dc.contributor.author","Becker, Stefan"],["dc.contributor.author","Zweckstetter, Markus"],["dc.date.accessioned","2017-09-07T11:44:43Z"],["dc.date.available","2017-09-07T11:44:43Z"],["dc.date.issued","2016"],["dc.description.abstract","N-15 spin-relaxation rates are demonstrated to provide critical information about the long-range structure and internal motions of membrane proteins. Combined with an improved calculation method, the relaxation-rate-derived structure of the 283-residue human voltage-dependent anion channel revealed an anisotropically shaped barrel with a rigidly attached N-terminal helix. Our study thus establishes an NMR spectroscopic approach to determine the structure and dynamics of mammalian membrane proteins at high accuracy and resolution."],["dc.identifier.doi","10.1002/anie.201602639"],["dc.identifier.gro","3141634"],["dc.identifier.isi","000383373700065"],["dc.identifier.pmid","27461260"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/3567"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1521-3773"],["dc.relation.issn","1433-7851"],["dc.title","High-Resolution NMR Determination of the Dynamic Structure of Membrane Proteins"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","451"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Alzheimer s Disease"],["dc.bibliographiccitation.lastpage","454"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Schmidt, Christian D."],["dc.contributor.author","Karch, Andre"],["dc.contributor.author","Artjomova, Svetlana"],["dc.contributor.author","Hoeschel, Martin"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T09:30:00Z"],["dc.date.available","2018-11-07T09:30:00Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: Pre-progression rates (PPR) in Alzheimer's disease (AD) have been reported to be associated with cognitive and functional decline. Objective: The objective was to reevaluate PPRs in a prospective cohort of AD patients. Methods: A prospective AD cohort was analyzed. Multiple regression was used to examine associations of PPRs with short term decline on different cognitive and functional scales (MMSE, instrumental and basic ADL, GDS, UPDRS III). Results: PPRs were only associated with first year instrumental ADL declines. Conclusion: The predictive abilities of PPRs could partially be confirmed. These findings can help to adapt patient care shortly after diagnosis."],["dc.identifier.doi","10.3233/JAD-130074"],["dc.identifier.isi","000318627800003"],["dc.identifier.pmid","23435410"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31196"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ios Press"],["dc.relation.issn","1387-2877"],["dc.title","Pre-Progression Rates in Alzheimer's Disease Revisited"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","215"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","CNS Spectrums"],["dc.bibliographiccitation.lastpage","218"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Schmidt, Christian D."],["dc.contributor.author","Plickert, Steffen"],["dc.contributor.author","Summers, David K."],["dc.contributor.author","Zerr, Inge"],["dc.date.accessioned","2018-11-07T08:44:26Z"],["dc.date.available","2018-11-07T08:44:26Z"],["dc.date.issued","2010"],["dc.identifier.isi","000276960400006"],["dc.identifier.pmid","20414170"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20193"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","M B L Communications, Inc"],["dc.relation.issn","1092-8529"],["dc.title","Pulvinar Sign in Wernicke's Encephalopathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1250"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","The Lancet Oncology"],["dc.bibliographiccitation.lastpage","1259"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Haenel, Mathias"],["dc.contributor.author","Borchmann, Peter"],["dc.contributor.author","Schmidt, Christian D."],["dc.contributor.author","Viardot, Andreas"],["dc.contributor.author","Bentz, Martin"],["dc.contributor.author","Peter, Norma"],["dc.contributor.author","Ehninger, Gerhard"],["dc.contributor.author","Doelken, Gottfried"],["dc.contributor.author","Ruebe, Christian"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Rosenwald, Andreas"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Glass, Bertram"],["dc.date.accessioned","2018-11-07T09:02:58Z"],["dc.date.available","2018-11-07T09:02:58Z"],["dc.date.issued","2012"],["dc.description.abstract","Background High-dose therapy (HDT) followed by transplantation of autologous haemopoietic stem cells is frequently done as part of first-line therapy in young patients with high-risk aggressive B-cell lymphoma. We investigated whether HDT with cytotoxic agents identical to those used for conventional therapy followed by autologous stem-cell transplantation (ASCT) improved survival outcome compared with conventional chemotherapy when rituximab was added to both modalities. Methods We did an open-label, randomised trial comparing conventional chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone) and rituximab (R-CHOEP-14) with dose-escalated sequential HDT and rituximab (R-MegaCHOEP) followed by repetitive ASCT in high-risk (age-adjusted International Prognostic Index [IPI] 2 or 3) patients aged 18-60 years with aggressive B-cell lymphoma. Eligible patients received radiotherapy for bulky, extranodal disease, or both. Randomisation (1: 1) used the Pocock minimisation algorithm; patients were stratified by age-adjusted IPI factors, bulky disease, and centre. The primary endpoint was event-free survival. All analyses were done on the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00129090. Findings 136 patients were randomly assigned to R-CHOEP-14 and 139 to R-MegaCHOEP. 130 patients in the R-CHOEP-14 group and 132 in the R-MegaCHOEP group were included in the intention-to-treat population. After a median of 42 months (IQR 29-59), 3-year event-free survival was 69.5% (95% CI 61.3-77.7) in the R-CHOEP-14 group and 61.4% (52.8-70.0) in the R-MegaCHOEP group (p=0.14; hazard ratio 1.3, 95% CI 0.9-2.0). All 128 evaluable patients treated with R-MegaCHOEP had grade 4 leucopenia, as did 48 (58.5%) of 82 patients with documented blood counts in the R-CHOEP-14 group. All 128 evaluable patients in the R-MegaCHOEP group had grade 3-4 thrombocytopenia, as did 26 (33.8%) of 77 patients in the R-CHOEP-14 group with documented blood counts. The most important non-haematological grade 3 or 4 adverse event was infection, which occurred in 96 (75.0%) of 128 patients treated with R-MegaCHOEP and in 40 (31.3%) of 128 patients treated with R-CHOEP-14. Interpretation In young patients with high-risk aggressive B-cell lymphoma, R-MegaCHOEP was not superior to conventional R-CHOEP therapy and was associated with significantly more toxic effects. R-CHOEP-14 with or without radiotherapy remains a treatment option for these patients, with encouraging efficacy."],["dc.description.sponsorship","Roche; Deutsche Krebshilfe [70-2732-pf4]"],["dc.identifier.doi","10.1016/S1470-2045(12)70481-3"],["dc.identifier.isi","000311509400042"],["dc.identifier.pmid","23168367"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24796"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1470-2045"],["dc.title","Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]